01-14-2015, 07:20 PM
The term molecular pharming or simply pharming refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). This method has also been used to produce useful products in the pharmaceutical industries to produce a number of therapies to different diseases. Unlike the usual genetic engineering processes, this method is considered less demanding in terms of infrastructure and costs. In the 21st century, Proof of concept has been established for the production of many therapeutic proteins, including antibodies, blood products, cytokines, growth factors, hormones, recombinant enzymes and human and veterinary vaccines through pharming. In February 2009 the United States FDA granted marketing approval for the first drug to be produced in genetically modified livestock. The drug is called ATryn, which is an antithrombin protein purified from the milk of genetically modified goats. Additionally, a most recent treatment for Gaucher’s disease has been approved. This drug is produced in cultured transgenic carrots and tobacco cells.